

## LITERATUR

## ÜBERSICHTSLITERATUR

- Baroff GS, Olley JG (1999). *Mental Retardation*. Philadelphia: Brunner/Mazel.
- Bouras N, Holt G (2007). *Psychiatric and Behavioral Disorders in Intellectual and Developmental Disabilities*. 2<sup>nd</sup> ed. Cambridge: Cambridge University Press.
- Cooper SA, Smiley E, Morrison J, Williamson A, Allan L, et al. (2007). Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. *Br J Psychiatry* 190: 27–35.
- Dosen A (2010). Psychische Störungen. Verhaltensprobleme und intellektuelle Behinderung: ein integrativer Ansatz für Kinder und Erwachsene. Göttingen: Hogrefe.
- Dosen A, Kenneth D (2001). *Treating Mental Illness and Behavior Disorders in Children and Adults with Mental Retardation*. Washington: American Psychiatric Press.
- Dosen A, Gardner W-I, Griffiths D-M, et al. (2010). *Praxisleitlinien und Prinzipien. Assessment, Diagnostik, Behandlung und Unterstützung für Menschen mit geistiger Behinderung und Problemverhalten – Europäische Edition*. 1. A. Berlin: Eigenverlag der DGSG, Band 21.
- Fletcher R, Loschen E, Stavrakaki C, First M (eds.) (2007). *Diagnostic Manual – Intellectual Disability (DM-ID). A Textbook of Diagnosis of Mental Disorders in Persons with Intellectual Disability*. Kingston, NY: NADD Press.
- Hassiotis A, Barron DA, Hall I (2009). *Intellectual Disability Psychiatry*. Chichester: Wiley-Blackwell.
- Raven JC, Raven J, Court JH (2006). *Coloured Progressive Matrices (CPM)*. Deutsche Bearbeitung und Normierung. Hrsg. von S. Bulheller und H. Häcker. Frankfurt/M.: Harcourt.
- Sappok T, Voß T, Millauer E et al. (2010). *Psychotherapie bei Menschen mit IM: Theoretischer Hintergrund und praktische Umsetzung*. *Nervenarzt* 81: 827–836.
- Schade C, Sappok T, Diefenbacher A (2008). Besonderheiten in der Diagnostik und Therapie psychischer Erkrankungen bei Menschen mit geistiger Behinderung. *Berl Arztebl* 121/239: 23–26.
- Schanze E (2007). *Psychiatrische Diagnostik und Therapie bei Menschen mit Intelligenzminderung: Ein Arbeits- und Praxisbuch*. Stuttgart: Schattauer.

## 24.1 TERMINOLOGIE

- APA – American Psychiatric Association (2000). *Diagnostic and Statistical Manual of Mental Disorders – Text Revision*, 4<sup>th</sup> ed. – DSM IV-TR. Washington, DC: American Psychiatric Press.
- APA – American Psychiatric Association (2013). *Diagnostic and Statistical Manual of Mental Disorders*, 5<sup>th</sup> ed. – DSM-5. Washington DC: American Psychiatric Press.
- APA – American Psychiatric Association (2015). *Diagnostisches und Statistisches Manual Psychischer Störungen DSM-5*. Deutsche Ausgabe hrsg. von P. Falkai und H-U Wittchen. Göttingen, Bern, Wien: Hogrefe.
- WHO – Weltgesundheitsorganisation (2005). *Internationale Klassifikation psychischer Störungen, ICD-10, Kapitel V (F)*. 5. A. Bern, Göttingen, Toronto: Huber.

## 24.2 EPIDEMIOLOGIE UND VERLAUF

- Herbst DS, Baird PA (1982). Sib risks for nonspecific mental retardation in British Columbia. *Am J Med Genet* 13: 197–208.

## 24.3 SYMPTOMATIK UND TYPISIERUNG

- Bittles AH, Petterson BA, Sullivan SG, et al. (2002). The influence of intellectual disability on life expectancy. *J Gerontol A Biol Sci Med Sci* 57: M470–472.
- Carr EG, Owen-Deschryver JS (2007). Physical illness, pain, and problem behavior in minimally verbal people with developmental disabilities. *J Autism Dev Disord* 37(3): 413–24.
- Cooper SA, Smiley E, Morrison J, et al. (2007). Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. *Br J Psychiatry* 190: 27–35.
- Dilling H, Mombour W, Schmidt MH (2011). *Internationale Klassifikation psychischer Störungen: ICD-10 Kapitel V (F)*. Klinisch-diagnostische Leitlinien. Bern: Huber.
- Elstner S, Weible H, Diefenbacher A (2011). Anforderungen an den „besonderen diagnostischen Blick“ bei Menschen mit geistiger Behinderung. *Med Men Geist Mehrf Beh* 8: 24–32.
- Emerson E, Bromley J (1995). The form and functioning of challenging behavior. *J Intell Disabil Res* 39: 388–398.
- Engel JM, Kartin D (2006). Pain in individuals with cerebral palsy. In: Oberlander TF, Symons FJ (eds.). *Pain in Children & Adults with Developmental Disabilities*. Baltimore: Paul H. Brookes, pp. 109–119.
- Felce D, Kerr M, Hastings RP (2009). A general practice based study of the relationship between indicators of mental illness and challenging behaviour among adults with intellectual disabilities. *J Intellect Disabil Res* 53: 243–254.
- Frankle ML, Heinrich M, Adam M et al. (2018). Körpergewicht und psychische Erkrankungen: Ergebnisse einer klinisch-psychiatrischen Querschnittsanalyse bei Menschen mit Intelligenzminderung. *Nervenarzt* 89(5): 552–558.
- Havercamp SM, Scandline D, Roth M (2004). Health disparities among adults with developmental disabilities, and adults not reporting disability in north Carolina. *Public Health Rep* 119: 418–426.
- Martin P (2017). Pain in Rett syndrome: peculiarities in pain processing and expression, liability to pain causing disorders and diseases, and specific aspects of pain assessment. *Adv in Autism* 3(3): 163–182.
- Patja K, Iivanainen M, Vesala H, et al. (2000). Life expectancy of people with intellectual disability: a 35-year follow up study. *J Intellect Disabil Res* 44: 591–599.
- Robertson J, Hatton C, Emerson E, Baines S (2015). Prevalence of epilepsy among people with intellectual disabilities: a systematic review. *Seizure* 29: 46–62.
- O'Hara J, McCarthy J, Bouras N (2010). *Intellectual Disability and Ill Health*. Cambridge: Cambridge University Press.
- Ryan R (2001). *Handbook of Mental Health Care for Persons with Developmental Disabilities*. Angus, Ontario: Diverse City Press Inc.
- Sappok T, Diefenbacher A (2017). *Die vierte Dimension*. Bielefeld: Bethel Verlag.
- Sappok T, Diefenbacher A (2011). Demenz und geistige Behinderung: Differentialdiagnostik und behandelbare Demenzen. *Med Men Geist Beh (Suppl)* 8: 39–45.
- Sappok T, Lindmeier B (2016). *Demenz bei geistiger Behinderung*. Kassel: Materialien der DGSG, Band 38.
- Sappok T, Barrett B, Voß T et al. (2009). Hashimoto-Thyreoiditis mit Hypothyreose und Hypokalziämie – Differentialdiagnostische Erwägungen bei Demenz und Down-Syndrom. *Med Men Geist Mehrf Beh* 6(1): 40–44.
- Sheehan R, Hassiotis A, Walters K (2015). Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population based cohort study. *BMJ* 351: h4326.
- Traci MA, Seekins T, Szali-Petree A, Ravesloot C (2002). Assessing secondary conditions among adults with developmental disabilities: a preliminary study. *Ment Retard* 40: 119–131.
- Tyler CV, Schramm S, Karafa M, et al. (2010). Electronic Health Record analysis of the primary care of adults with intellectual and other developmental disabilities. *J Policy Pract Intellect Disabil* 3: 204–210.
- Voß T, Diefenbacher A (2009). Diagnostik und Therapie von Demenzerkrankungen bei Menschen mit Intelligenzminderung. In: Mahlberg R, Gutzmann H (Hrsg.). *Demenzerkrankungen erkennen, behandeln und versorgen*. Köln: Deutscher Ärzteverlag, S. 96–100.
- Walsh M, Morrison TG, McGuire BE (2011). Chronic pain in adults with an intellectual disability: Prevalence, impact, and health service use based on caregiver report. *Pain* 152 (9): 1951–1957.
- Walter-Fränk S (2018). *Schmerzdiagnostik*. In: Sappok T (Hrsg.). *Co-Production: Ein Lehrbuch zur psychischen Gesundheit bei intellektueller Entwicklungsstörung*. Stuttgart: Kohlhammer.

## 24.4 AUTISMUS-SPEKTRUM-STÖRUNGEN

- AWMF – Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (2016). Autismus-Spektrum-Störungen im Kindes-, Jugend- und Erwachsenenalter. Teil 1: Diagnostik. ([www.awmf.org/uploads/tx\\_szleitlinien/028-018l\\_S3\\_Autismus-Spektrum-Stoerungen\\_ASS-Diagnostik\\_2016-05.pdf](http://www.awmf.org/uploads/tx_szleitlinien/028-018l_S3_Autismus-Spektrum-Stoerungen_ASS-Diagnostik_2016-05.pdf), Zugriff am 17.4.2018).
- Bachmann CJ, Manthey T, Kamp-Becker I, et al. (2013). Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. *Res Dev Disabil* 34(9): 2551–2563.
- Bölte S (Hrsg.) (2009). Autismus. 1. A. Bern: Huber.
- Bulheller S, Häckler H (2002). Coloured Progressive Matrices (CPM). 3<sup>rd</sup> ed. Frankfurt/M.: Pearson Assessment.
- Cooper SA, Smiley E, Morrison J, et al. (2007). Mental ill-health in adults with intellectual disabilities: prevalence and associated factors. *Br J Psychiatry* 190: 27–35.
- de la Torre-Ubieta L, Won H, Stein JL, Geschwind DH (2016). Advancing the understanding of autism disease mechanisms through genetics. *Nat Med* 22(4): 345–361.
- Deutsche Gesellschaft für Kinder- und Jugendpsychiatrie und Psychotherapie (Hrsg.) (2007). Leitlinien zur Diagnostik und Therapie von psychischen Störungen im Säuglings-, Kindes- und Jugendalter. 3. A. Köln: Deutscher Ärzte Verlag.
- Dosen A (2010). Psychische Störungen, Verhaltensprobleme und intellektuelle Behinderung: Ein integrativer Ansatz für Kinder und Erwachsene. Göttingen: Hogrefe.
- Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG (2009). A longitudinal investigation of psychotropic and nonpsychotropic medication use among adolescents and adults with autism spectrum disorders. *J Aut Dev Disord* 39: 1339–1349.
- Ghanizadeh A, Sahraeizadeh A, Berk M (2014). A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. *Child Psychiatry Hum Dev* 45(2): 185–192.
- Hsia Y, Wong AY, Murphy DG, et al. (2014). Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study. *Psychopharmacology (Berl)* 231(6): 999–1009.
- Heinrich M, Böhm J, Sappok T (2018). Diagnosing autism in adults with intellectual disability: validation of the DiBAS-R in an independent sample. *J Autism Dev Disord* 48(2): 341–350.
- Hirvikoski T, Mittendorfer-Rutz E, Boman M, et al. (2016). Premature mortality in autism spectrum disorder. *Br J Psychiatry* 208(3): 232–238.
- Kanner L (1943). Autistic disturbances of affective contact. *Nervous Child* 2: 217–250.
- Kraijer D, de Bildt (2005). The PDD-MRS: an instrument for identification of autism spectrum disorders in persons with mental retardation. *J Aut Dev Disord* 35: 499–513.
- Lord C, Rutter M, DiLavore P, et al. (2001). Autism Diagnostic Observation Schedule (ADOS). Los Angeles: Western Psychological Services.
- Matson JL, Shoemaker M (2009). Intellectual disability and its relationship to autism spectrum disorders. *Res Dev Disabil* 30: 1107–1114.
- Mesibov GB, Schopler E, Schaffer B et al. (2000). AAPEP-Entwicklungs- und Verhaltensprofil für Jugendliche und Erwachsene. Dortmund: Verlag Modernes Leben.
- Mesibov GB, Shea V, Schopler E (2004). The TEACCH Approach to Autism Spectrum Disorders. New York: Springer.
- NICE – National Institute for Health and Clinical Excellence (2012) Autism in adults: diagnosis and management; [www.nice.org.uk/guidance/cg142/chapter/1-guidance](http://www.nice.org.uk/guidance/cg142/chapter/1-guidance) (letzter Zugriff: 17.4.2018).
- Pickles A, Le Couteur A, Leadbitter K, et al. (2016). Parent-mediated social communication therapy for young children with autism (PACT): long-term follow-up of a randomised controlled trial. *Lancet* 388(10059): 2501–2509.
- Rutter M, Le Couteur A, Lord C (2003). Autism Diagnostic Interview-Revised (ADI-R). Los Angeles: Western Psychological Services.
- Sahin M, Sur M (2015). Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders. *Science* 350(6263): pii: aab3897.
- Sappok T (2013). Autismspektrumstörungen. In: Schanze C (Hrsg.). Psychiatrische Diagnostik und Therapie bei Menschen mit Intelligenzminderung. 2. A. Stuttgart: Schattauer, S. 257–278.
- Sappok T, Bergmann T, Kaiser H et al. (2010). Autismus bei erwachsenen Menschen mit geistiger Behinderung. *Nervenarzt* 11: 1333–1345.
- Sappok T, Budczies J, Bölte S, et al. (2013a). Emotional development in adults with autism and intellectual disabilities: a retrospective, clinical analysis. *PLoS One* 8(9): e74036.
- Sappok T, Diefenbacher A, Budczies J, et al. (2013b). Diagnosing autism in a clinical sample of adults with intellectual disabilities – how useful are the ADOS and the ADI-R? *Res Dev Disabil* 34: 1642–1655.
- Sappok T, Kienitz L, Bergmann T (2013c). Autismus – Diagnostik, Therapie und Förderung. Bielefeld: Bethel-Verlag, Epub.
- Sappok T, Budczies J, Dziobek I, et al. (2014a). The missing link: Delayed emotional development predicts challenging behavior in adults with intellectual disability. *J Aut Dev Disord* 44: 786–800.
- Sappok T, Gaul I, Bergmann T, et al. (2014b). The Diagnostic Behavioral Assessment for autism spectrum disorder – Revised: A screening instrument for adults with intellectual disability suspected of autism spectrum disorders. *Res Aut Spectr Dis* 8: 362–375.
- Sappok T, Heinrich M, Diefenbacher A (2014c). Psychometrische Eigenschaften der Autismus-Checkliste (ACL) für erwachsene Menschen mit Intelligenzminderung. *Psych Praxis* 41: 37–44.
- Schopler E, Reichler RJ, Bashford A, et al. (2005). Psychoeducational Profile (PEP-3): TEACCH Individualized Psychoeducational Assessment. 3<sup>rd</sup> ed. Austin, Texas: Pro-ed.
- Simonoff E, Pickles A, Charman T, et al. (2008). Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. *J Am Acad Child Adolesc Psychiatry* 47: 921–929.
- Steinhausen HC, Mohr Jensen C, Lauritsen MB (2016). A systematic review and meta-analysis of the long-term overall outcome of autism spectrum disorders in adolescence and adulthood. *Acta Psychiatr Scand* 133(6): 445–452.
- [www.people1.de](http://www.people1.de) (letzter Zugriff: 17.4.2018).

## 24.5 ÄTIOLOGIE UND PATHOGENESE

- AWMF (2016). S3-Leitlinie Fetale Alkoholspektrumstörungen (FASD); [www.awmf.org/leitlinien/detail/II/022-025.html](http://www.awmf.org/leitlinien/detail/II/022-025.html) (letzter Zugriff: 17.4.2018).
- Deciphering Developmental Disorders Study (2017). Prevalence and architecture of de novo mutations in developmental disorders. *Nature* 23: 433–438.
- Laucht M, Esser G, Schmidt MH (1998). Risiko- und Schutzfaktoren der kindlichen Entwicklung – empirische Befunde. *Z Kinder Jugendpsychiatr Psychother* 26: 6–20.
- Laucht M, Schmidt MH (2002). Motorische, kognitive und sozial-emotionale Entwicklung von 11-Jährigen mit frühkindlichen Risikobelastungen: späte Folgen. *Z Kinder Jugendpsychiatr Psychother* 30: 5–19.
- Meyer-Probst B, Reis O (1999). Lebenslaufforschung von der Geburt bis 25. Rostocker Längsschnittstudie (ROLS). *Kindheit und Entwicklung* 8: 59–68.
- Visser LE, Gilissen C, Veltman JA (2016). Genetic studies in intellectual disability and related disorders. *Nat Rev Genet* 17: 9–18.
- Wallander JL, Dekker MC, Koot HM (2006). Risk factors for psychopathology in children with intellectual disability: a prospective longitudinal population-based study. *J Intellect Disabil Res* 50: 259–268.
- Wolke D, Meyer R (1999). Ergebnisse der bayrischen Entwicklungsstudie: Implikationen für Theorie und Praxis. *Kindheit und Entwicklung* 8: 23–35.
- Zweier C (2018a). Genetische Diagnostik. In: Sappok T (Hrsg.). Psychische Gesundheit bei intellektueller Entwicklungsstörung. Stuttgart: Kohlhammer.
- Zweier C (2018b). Genetische Störungen. In: Sappok T (Hrsg.). Psychische Gesundheit bei intellektueller Entwicklungsstörung. Stuttgart: Kohlhammer.

## 24.6 DIFFERENZIALDIAGNOSTISCHER PROZESS

- Airaksinen EM, Matilainen R, Mononen T, et al. (2000). A population-based study on epilepsy in mentally retarded children. *Epilepsia* 41: 1214–1220.
- Corbett JA, Harris R, Robinson RG (1975). Epilepsy. In: Wortis J (ed.). *Mental Retardation and Developmental Disabilities*. Vol. VII. New York: Brunner/Mazel, pp. 79–111.
- Evenhuis HM (1996). Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR). *J Intellect Disabil Res* 40: 369–373.
- Huber B (2004). Epilepsien bei geistiger Behinderung. In: Hässler F, Fegert JM (Hrsg.). *Geistige Behinderung und seelische Gesundheit. Geistige Behinderung und seelische Gesundheit*. Stuttgart: Schattauer, S. 193–251.
- Kaufman AS, Kaufman NL (2015). *Kaufman Assessment Battery for Children – Second Edition (KABC-2)*. Göttingen: Hogrefe.
- Kuske B, Müller SV (2017). Demenz-Früherkennung bei Menschen mit Intelligenzminderung – eine Pilotstudie zur Anwendbarkeit des Demenzttests für Menschen mit Intelligenzminderung (DTIM). *Zeitschrift für Neuropsychologie* 28: 219–229.
- Liepmann MC (1979). *Geistig behinderte Kinder und Jugendliche. Eine epidemiologische, klinische und sozialpsychologische Studie in Mannheim*. Bern, Göttingen, Toronto: Huber.
- Petermann (2012). *Wechsler Adults Intelligence Scale – Forth Edition*. Frankfurt: Pearson Assessment.
- Raven JC, Raven J, Court JH (2006). *Coloured Progressive Matrices (CPM)*. Deutsche Bearbeitung und Normierung. Frankfurt a. M.: Harcourt.
- Sappok T, Budczies J, Bölte S, et al. (2013a). Emotional development in adults with autism and intellectual disabilities: a retrospective, clinical analysis. *PLoS One* 8(9): e74036.
- Sappok T, Diefenbacher A, Budczies J, et al. (2013b). Diagnosing autism in a clinical sample of adults with intellectual disabilities – How useful are the ADOS and the ADI-R? *Res Dev Disabil* 34: 1642–1655.
- Sappok T, Heinrich M, Diefenbacher A (2013c). Psychometrische Eigenschaften der Autismus-Checkliste (ACL) für erwachsene Menschen mit Intelligenzminderung. *Psych Praxis* 40: 1–8.
- Sappok T, Barrett BF, Vandevelde S, et al. (2016). Scale of emotional development - Short. *Res Dev Disabil* 7(59): 166–175.
- Sappok T, Zepperitz S, Barrett BF, Došen A (2018). *Skala der emotionalen Entwicklung – Diagnostik (SEE-D) – Diagnostik*. Bern: Hogrefe.
- Tellegen PJ, Laros JA, Petermann F (2012). *Snijders-Oomen Non-verbaler Intelligenztest: SON-R 6-40. 1. A.* Göttingen: Hogrefe.
- van Karnebeek CD, Jansweijer MC, Leenders AG, et al. (2005). Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. *Eur J Hum Genet* 13: 6–25.
- Wiedemann HR, Grosse KR, Dibbern H (1985). *Das charakteristische Syndrom*. Stuttgart, New York: Schattauer.
- Didden R, Duker PC, Korzilius H (1997). Meta-analytic study on treatment effectiveness for problem behaviors with individuals who have mental retardation. *Am J Ment Retard* 101: 387–399.
- Dosen A (1993). Diagnosis and treatment of psychiatric and behavioural disorders in mentally retarded individuals: The state of the art. *J Intellect Disabil Res* 37 (suppl 1): 1–7.
- Emerson E (1993). Challenging behaviours and severe learning disabilities: Recent developments in behavioural analysis and intervention. *Behav Cog Psychother* 21: 171–198.
- Fletcher-Watson S, McConnell F, Manola E, McConachie H (2014). Interventions based on the Theory of Mind cognitive model for autism spectrum disorder (ASD). *Cochrane Database Syst Rev* 3: CD008785.
- French L, Kennedy EMM (2018). Research Review: Early intervention for infants and young children with, or at-risk of, autism spectrum disorder: a systematic review. *J Child Psychol Psychiatry* 59(4): 444–456.
- Hässler F, Reis O (2010). Pharmacotherapy of disruptive behaviour in mentally retarded subjects: A review of the current literature. *Dev Disabil Res Rev* 16: 265–272.
- Hässler F, Buchmann J, Reis O (2005). *Psychopharmaka und Polypharmazie. Die Behandlung von Menschen mit geistiger Behinderung*. Nervenheilkunde 24: 811–818.
- Hässler F, Glaser T, Pap AF, et al. (2008). A double-blind placebo-controlled discontinuation study of zuclopenthixol for the treatment of aggressive disruptive behaviours in adults with mental retardation – secondary parameter analyses. *Pharmacopsychiatry* 41: 232–239.
- Harris J (1996). *Physical Restraint Procedures for Managing Challenging Behaviours Presented by Mentally Retarded Adults and Children*. *Res Dev Disabil* 17: 99–134.
- Kahng S, Iwata BA, Lewi AB (2002). Behavioral treatment of self-injury, 1964 to 2000. *Am J Ment Retard* 107: 212–221.
- Lancioni GE, Cuvo AJ, O'Reilly MF (2002). Snoezelen: an overview of research with people with developmental disabilities and dementia. *Disabil Rehabil* 24: 175–184.
- Kalachnik JE, Hanzel TE, Sevenich R, Harder SR (2002). Benzodiazepine behavioral side effects: review and implications for individuals with mental retardation. *Am J Ment Retard* 107: 376–410.
- Lott IT, McGregor M, Engelman L, et al. (2004). Longitudinal prescribing patterns for psychoactive medications in community-based individuals with developmental disabilities: utilization of pharmacy records. *J Intellect Disabil Res* 48: 563–571.
- NICE Guideline (2015). Challenging behavior and learning disabilities: prevention and interventions for people with learning disabilities whose behavior challenges; [www.nice.org.uk/guidance/ng11](http://www.nice.org.uk/guidance/ng11) (letzter Zugriff: 17.4.2018).
- NICE Guideline (2016). Mental health problems in people with learning disabilities: prevention, assessment and management; [www.nice.org.uk/guidance/ng54](http://www.nice.org.uk/guidance/ng54) (letzter Zugriff: 17.4.2018).
- Rana F, Gormez A, Varghese S (2013). Pharmacological interventions for self-injurious behaviour in adults with intellectual disabilities. *Cochrane Database Syst Rev* 4: CD009084.
- Rave-Schwank M (1988). *Geistige Behinderung: pädagogische Förderung und psychiatrische Behandlung*. In: Böcker F, Weig W (Hrsg.). *Aktuelle Kernfragen in der Psychiatrie*. Berlin, Heidelberg, New York: Springer, S. 285–290.
- Rummans TA, Lauterbach EC, Coffey CE, et al. (1999). Pharmacologic efficacy in neuropsychiatry: a review of placebo-controlled treatment trials. A report of the ANPA Committee on Research. *J Neuropsychiatry Clin Neurosci* 11(2): 176–189.
- Sovner R, Hurley AD (1983). Do the mentally retarded suffer from affective illness? *Arch Gen Psychiatry* 40(1): 61–67.
- Spreat S, Conroy JW, Fullerton A (2004). Statewide longitudinal survey of psychotropic medication use for persons with mental retardation: 1994 to 2000. *Am J Ment Retard* 109: 322–331.
- Vargas S, Camilli G (1999). A meta-analysis of research on sensory integration treatment. *Am J Occup Ther* 53: 189–198.

## 24.7 THERAPIE

- AWMF (2014). S2k Praxisleitlinie Intelligenzminderung. AWMF-Register Nr. 028-042; [www.awmf.org/uploads/tx\\_szleitlinien/028-042\\_S2k\\_Intelligenzminderung\\_2014-12.pdf](http://www.awmf.org/uploads/tx_szleitlinien/028-042_S2k_Intelligenzminderung_2014-12.pdf) (letzter Zugriff: 17.4.2018).
- Berg R, Burian R, Delcamp A et al. (2010). *Medikamentenverordnung in der ambulanten psychiatrischen Versorgung in Berlin – eine Pilotstudie*. *Soziale Psychiatrie* 24(4): 44–46.
- Branford D (1994). A study of the prescribing for people with learning disabilities living in the community and in National Health Service care. *J Intellect Disabil Res* 38: 577–586.
- Buzan RD, Thomas M, Dubovsky SL, Treadway J (1995). The use of opiate antagonists for recurrent self-injurious behavior. *J Neuropsychiatry Clin Neurosci* 7: 437–444.
- Canadian Consensus Guidelines (2011). Primary care of adults with developmental disabilities. *Can Fam Physician* 57: 541–553.
- Chanas AK, Reid G, Hoover ML (1998). Exercise effects on health-related physical fitness of individuals with an intellectual disability: a meta-analysis. *Adapted Phys Activity Q* 15: 119–140.

**24.8 RECHTLICHE UND GESETZLICHE BESTIMMUNGEN**ICF: [www.dimdi.de](http://www.dimdi.de)**SYSTEMATISCHE COCHRANE-REVIEWS ([WWW.COCHRANE.DE/DEUTSCH](http://WWW.COCHRANE.DE/DEUTSCH))**

- Brylewski J, Duggan L (2004). Antipsychotic medication for challenging behaviour in people with learning disability. Cochrane Database Syst Rev 3: CD000377.
- Cheuk DKL, Wong V, Chen WX (2011). Acupuncture for autism spectrum disorders (ASD). Cochrane Database Syst Rev 9: CD007849.
- Duggan L, Brylewski J (2004). Antipsychotic medication versus placebo for people with both schizophrenia and learning disability. Cochrane Database Syst Rev 4: CD000030.
- Geretsegger M, Elefant C, Kim J, Gold C (2014). Music therapy for people with autism spectrum disorder. Cochrane Database Syst Rev 6: CD004381.
- Hirsch LE, Pringsheim T (2016). Aripiprazole for autism spectrum disorders (ASD). Cochrane Database Syst Rev 6: CD009043.
- Hurwitz R, Blackmore R, Hazell P, et al. (2012). Tricyclic antidepressants for autism spectrum disorders (ASD) in children and adolescents. Cochrane Database Syst Rev 3: CD008372.
- James S, Montgomery P, Williams K (2011). Omega-3 fatty acids supplementation for autism spectrum disorders (ASD). Cochrane Database Syst Rev 11: CD00799.
- James S, Stevenson SW, Silove N, Williams K (2015). Chelation for autism spectrum disorder (ASD). Cochrane Database Syst Rev 5: CD010766.
- Jesner OS, Aref-Adib M, Coren E (2007). Risperidone for autism spectrum disorder. Cochrane Database Syst Rev 1: CD005040.
- Millward C, Ferriter M, Calver SJ, Connell-Jones G (2008). Gluten- and casein-free diets for autistic spectrum disorder. Cochrane Database Syst Rev 2: CD003498.
- Nye C, Brice A (2005). Combined vitamin B6-magnesium treatment in autism spectrum disorder. Cochrane Database Syst Rev 4: CD00349.
- Reichow B, Steiner AM, Volkmar F (2013). Social skills groups for people aged 6 to 21 with autism spectrum disorders (ASD). Cochrane Database Syst Rev 7: CD008511.
- Reichow B, Barton EE, Boyd BA, et al. (2012). Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 10: CD009260.
- Sinha Y, Silove N, Hayen A, et al. (2011). Auditory integration training and other sound therapies for autism spectrum disorders (ASD). Cochrane Database Syst Rev 12: CD003681.
- Sturman N, Deckx L, van Driel ML (2017). Methylphenidate for children and adolescents with autism spectrum disorder. Cochrane Database Syst Rev 11: CD011144.
- Oono IP, Honey EJ, McConachie H (2013). Parent-mediated early intervention for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 4: CD009774.
- Williams K, Wray JA, Wheeler DM (2012). Intravenous secretin for autism spectrum disorders (ASD). Cochrane Database Syst Rev 4: CD003495.
- Williams K, Brignell A, Randall M, et al. (2013). Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev 8: CD004677.
- Xiong T, Chen H, Luo R, Mu D (2016). Hyperbaric oxygen therapy for people with autism spectrum disorder (ASD). Cochrane Database Syst Rev 10: CD010922.